Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1988 | Intervention group CoronaCope Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003863 | Depression, NIH | 0.11 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Patients on dialysis are at risk for several infectious diseases, since they have reduced immunological and have to regularly attend dialysis centres even if a pandemic is going on. Dialysis patients and healthcare professionals of dialysis centres can become infected one with the other. The incident risk of COVID-19 in dialysis centres is still unknown. Given the challenges of an early diagnosis of COVID-19, the likely transmission with outbreaks, the possibility of reciprocal transmission of the infection among patients and healthcare professionals, the frequent clinical severity of COVID-19 in dialysis patients because of the coexistence of several comorbidities, CONTACT TRACING could be an effective and efficient tool to contrast COVID-19 spreading in dialysis centres.
Description: incident risk of COVID-19 infection in dialysis patients and in related dialysis healthcare professionals
Measure: incident risk of COVID-19 infection Time: 1 yearDescription: Evaluate the morbidity (hospitalisation rate) of COVID-19 in the two subject categories
Measure: Evaluate the morbidity of COVID-19 Time: 1 yearDescription: Evaluate the mortality rate of COVID-19 in the two subject categories
Measure: Evaluate the mortality of COVID-19 Time: 1 yearDescription: Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate in the three months after COVID-19 diagnosis
Measure: Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate Time: Three monthsDescription: Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate in the three months after COVID-19 diagnosis
Measure: Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate Time: Three monthsDescription: Evaluate the infective role of dialysis staff towards patients over one year follow-up
Measure: Evaluate the infective role of dialysis staff towards patients Time: 1 yearDescription: Evaluate the infective role of patients towards dialysis staff over one year follow-up
Measure: Evaluate the infective role of patients towards dialysis staff Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports